Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities researchers at Citigroup to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also weighed in on the company. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Barclays lowered their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Evercore ISI decreased their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Finally, Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 3.3 %

Regeneron Pharmaceuticals stock traded down $25.66 during mid-day trading on Wednesday, hitting $756.85. 427,639 shares of the company’s stock were exchanged, compared to its average volume of 526,192. Regeneron Pharmaceuticals has a 1-year low of $753.69 and a 1-year high of $1,211.20. The stock has a 50 day moving average of $992.70 and a two-hundred day moving average of $1,033.92. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $83.17 billion, a P/E ratio of 18.93, a P/E/G ratio of 3.04 and a beta of 0.15.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 25.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares in the last quarter. Swedbank AB bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at about $129,257,000. Finally, Epoch Investment Partners Inc. acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth about $99,667,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.